News
PRTA
24.43
-1.45%
-0.36
Unpleasant Surprises Could Be In Store For Prothena Corporation plc's (NASDAQ:PRTA) Shares
Prothena Corporation plc (NASDAQ:PRTA) has a price-to-sales ratio of 14.9x. The company's revenue growth has been slower than most of its industry peers. Despite this, the company's P/S is higher than the average for biotechs companies. It's expected to grow revenue by 40% over the next three years, but the industry is growing by 193%.
Simply Wall St · 16h ago
Weekly Report: what happened at PRTA last week (0715-0719)?
Weekly Report · 4d ago
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
NASDAQ · 07/15 11:39
Weekly Report: what happened at PRTA last week (0708-0712)?
Weekly Report · 07/15 09:15
Weekly Report: what happened at PRTA last week (0701-0705)?
Weekly Report · 07/08 09:15
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
NASDAQ · 07/03 12:34
June 2024 New Analysts Cover Uber, TG Therapeutics, CarMax, And More
21 new analysts joined Seeking Alpha in June and are highlighted today. They cover a range of sectors including biotech, technology, consumer staples, and real estate. New analysts cover Uber, TG Therapeutics, CarMax, Grab Holdings, and more. Each is highlighted with their first-ever investment thesis on Seeking Alpha.
Seeking Alpha · 07/02 17:00
Weekly Report: what happened at PRTA last week (0624-0628)?
Weekly Report · 07/01 09:15
Prothena Price Target Maintained With a $28.00/Share by RBC Capital
Dow Jones · 06/26 15:12
RBC Capital Reiterates Sector Perform on Prothena Corp, Maintains $28 Price Target
Benzinga · 06/26 15:05
Prothena (PRTA) Receives a Hold from RBC Capital
TipRanks · 06/26 10:27
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
NASDAQ · 06/24 12:48
Weekly Report: what happened at PRTA last week (0617-0621)?
Weekly Report · 06/24 09:16
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
NASDAQ · 06/19 17:00
Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth
Prohena (NASDAQ:PRTA) has seen its annual cash burn increase by 36% last year. The company is burning through cash to fund its growth. In March 2024, Prothena had US$547m in cash, and is debt-free. However, analysts predict the company will reach breakeven in 4 years. We don't think shareholders should be concerned about the company's cash burn. Its revenue growth suggests the company is on a good path to growing.
Simply Wall St · 06/19 10:26
Weekly Report: what happened at PRTA last week (0610-0614)?
Weekly Report · 06/17 09:15
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
NASDAQ · 06/14 15:21
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
NASDAQ · 06/14 15:10
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
NASDAQ · 06/13 10:09
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
NASDAQ · 06/12 14:22
More
Webull provides a variety of real-time PRTA stock news. You can receive the latest news about Prothena through multiple platforms. This information may help you make smarter investment decisions.
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.